/clinical/,/clinical/cckm-tools/,/clinical/cckm-tools/content/,/clinical/cckm-tools/content/beacon-protocols/,/clinical/cckm-tools/content/beacon-protocols/gyn/,

/clinical/cckm-tools/content/beacon-protocols/gyn/name-96760-en.cckm

201706157

page

100

UWHC,UWMF,

Clinical Hub,UW Health Clinical Tool Search,UW Health Clinical Tool Search,Beacon Protocols,GYN

CSC GYN Ifosfamide Mesna(21D:1-5) No Prior XRT VER 1-11-17 (HL 446)

CSC GYN Ifosfamide Mesna(21D:1-5) No Prior XRT VER 1-11-17 (HL 446) - Clinical Hub, UW Health Clinical Tool Search, UW Health Clinical Tool Search, Beacon Protocols, GYN


CSC GYN IFOSFAMIDE/MESNA (21D:1-5) NO PRIOR XRT VER: 1-11-17 – Properties
Pre-Cycle – 5/30/2017 through 6/5/2017 (7 days), Planned
Day 1, Pre-Cycle – Planned for 5/30/2017
Treatment Plan Information
Treatment Plan Summary
DISEASE: Cervical Cancer (Advanced) Vulvar/Vaginal (Advanced) and Uterine Sarcoma (Adjuvant/Advanced); THERAPY: mesna
500 mg/m2 IV prior ifosfamide on Day 1 through 5; ifosfamide 1500 mg/m2 IV on Day 1 through 5; mesna 500 mg/m2 by mouth 4
hours and 8 hours after the start of ifosfamide; CYCLE LENGTH: 21 days; COURSE: 6 cycles.
Note: If prior radiotherapy or chemotherapy give ifosfamide 1200 mg/m2 IV on Day 1 through 5.
Consent
Verify Consent
Verify informed consent has been obtained.
Pre-Labs
CBC WITHOUT DIFFERENTIAL
Expected-S Approximate, Expires-S+365, Routine
ABSOLUTE NEUTROPHIL COUNT
Expected-S Approximate, Expires-S+365, Routine
ELECTROLYTES
Expected-S Approximate, Expires-S+365, Routine
MAGNESIUM
Expected-S Approximate, Expires-S+365, Routine
GLUCOSE
Expected-S Approximate, Expires-S+365, Routine
BUN
Expected-S Approximate, Expires-S+365, Routine
CREATININE
Expected-S Approximate, Expires-S+365, Routine
BILIRUBIN, TOTAL
Expected-S Approximate, Expires-S+365, Routine
URINALYSIS, NO MICROSCOPY
Expected-S Approximate, Expires-S+365, Normal, Routine
Take Home Medications
ondansetron (ZOFRAN) 8 MG tab
Take 1 tab orally twice daily on Day 6 and 7 then 1 tab every 8h as needed for nausea, Disp-30 tab, R-5, starting S, Local Printer
Cycle 1 – 6/6/2017 through 6/26/2017 (21 days), Planned
Day 1, Cycle 1 – Planned for 6/6/2017
Treatment Plan Information
Reference Information (1)
CERVICAL CANCER: Sutton G, et al. Am J Obstet Gynecol 1993; 168:805-7.
Reference Information (2)
UTERINE SARCOMA: Sutton G, et al. Am J Obstet Gynecol 1998; 161:309-12.
Treatment Plan Summary
DISEASE: Cervical Cancer (Advanced) Vulvar/Vaginal (Advanced) and Uterine Sarcoma (Adjuvant/Advanced); THERAPY: mesna
500 mg/m2 IV prior ifosfamide on Day 1 through 5; ifosfamide 1500 mg/m2 IV on Day 1 through 5; mesna 500 mg/m2 by mouth 4
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
6/6/2017 5:07:26 PM Page 1 of 40
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 06/2017CCKM@uwhealth.org

hours and 8 hours after the start of ifosfamide; CYCLE LENGTH: 21 days; COURSE: 6 cycles.
Note: If prior radiotherapy or chemotherapy give ifosfamide 1200 mg/m2 IV on Day 1 through 5.
Consent
Verify Consent
Verify informed consent has been obtained.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Treatment Conditions
Verify Labs
Verify pretreatment labs have been obtained and resulted: CBC, ANC, Urine Heme.
Monitoring Parameters (1)
Hold and notify authorizing prescriber for ANC less than or equal to 1,500/µL or Platelets less than or equal to 100K/µL or Urine
Hemoglobin greater than Trace or Creatinine greater than upper limits of normal.
Nursing Procedure, Assessment and Monitoring
Flush Venous Access Device per Guidelines
Order details
sodium chloride flush 0.9% 10 mL injection
Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin lock flush 10 UNIT/ML injection 1-150 units
1-150 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin 100 UNIT/ML lock flush injection 500 units
500 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Implanted port use ONLY to be used when de-accessing port. Flush per VAD guidelines.
Hydration
sodium chloride 0.9 % infusion
at 250-500 mL/hr, Intravenous, ONCE, 1 dose Starting when released
Infuse 1000 mL throughout treatment.
Pre-Medications
ondansetron (ZOFRAN) tab 16 mg
16 mg, Oral, ONCE, 1 dose Starting when released
dexamethasone (DECADRON) tab 10 mg
10 mg, Oral, ONCE, 1 dose Starting when released
Treatment Medications
mesna (MESNEX) 1,000 mg in sodium chloride 0.9 % 50 mL bag
1,000 mg (500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
ifosfamide (IFEX) 3,000 mg in sodium chloride 0.9 % 250 mL bag
3,000 mg (1,500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
If prior radiotherapy or chemotherapy give ifosfamide 1200mg/m2 IV once daily for 5 days.
Take Home Medications
mesna (MESNEX) 400 MG tab
Take 2.5 tabs by mouth 2 times daily. Take 4 & 8 hours after start of ifosfamide Day 1 thru 5., 1,000 mg (500 mg/m2 × 2 m2
Treatment plan BSA from recorded weight), R-0, 2 X DAILY starting S
Follow-Up
DAY 2 FOLLOW-UP
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
6/6/2017 5:07:26 PM Page 2 of 40
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 06/2017CCKM@uwhealth.org

LABS: Urinalysis without Microscopy; CHEMOTHERAPY ROOM APPOINTMENT: ifosfamide and mesna for 200
minutes.
DAY 3 FOLLOW-UP
LABS: Urinalysis without Microscopy; CHEMOTHERAPY ROOM APPOINTMENT: ifosfamide and mesna for 200 minutes.
DAY 4 FOLLOW-UP
LABS: Urinalysis without Microscopy; CHEMOTHERAPY ROOM APPOINTMENT: ifosfamide and mesna for 200 minutes.
DAY 5 FOLLOW-UP
LABS: Urinalysis without Microscopy; CHEMOTHERAPY ROOM APPOINTMENT: ifosfamide and mesna for 200 minutes.
DAY 10 FOLLOW-UP
LABS: CBC, ANC (DIFF if to be done locally)
DAY 22 FOLLOW-UP
(Day 1 of next cycle) RETURN TO CLINIC for appointment with provider; LABS: CBC, ANC (DIFF if to be done locally), Electrolytes,
Magnesium, Glucose, BUN, Creatinine, Urinalysis without Microscopy; CHEMOTHERAPY ROOM APPOINTMENT: ifosfamide and
mesna for 200 minutes.
Day 2, Cycle 1 – Planned for 6/7/2017
Treatment Plan Information
Treatment Plan Summary
DISEASE: Cervical Cancer (Advanced) Vulvar/Vaginal (Advanced) and Uterine Sarcoma (Adjuvant/Advanced); THERAPY: mesna
500 mg/m2 IV prior ifosfamide on Day 1 through 5; ifosfamide 1500 mg/m2 IV on Day 1 through 5; mesna 500 mg/m2 by mouth 4
hours and 8 hours after the start of ifosfamide; CYCLE LENGTH: 21 days; COURSE: 6 cycles.
Note: If prior radiotherapy or chemotherapy give ifosfamide 1200 mg/m2 IV on Day 1 through 5.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
URINALYSIS, NO MICROSCOPY
Expected-S+1 Approximate, Expires-S+365, Normal, Routine
Treatment Conditions
Verify Labs
Verify pretreatment labs have been obtained and resulted: Urine Heme.
Treatment Parameters
Hold and notify authorizing prescriber for Urine Hemoglobin greater than Trace.
Nursing Procedure, Assessment and Monitoring
Flush Venous Access Device per Guidelines
Order details
sodium chloride flush 0.9% 10 mL injection
Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin lock flush 10 UNIT/ML injection 1-150 units
1-150 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin 100 UNIT/ML lock flush injection 500 units
500 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Implanted port use ONLY to be used when de-accessing port. Flush per VAD guidelines.
Hydration
sodium chloride 0.9 % infusion
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
6/6/2017 5:07:26 PM Page 3 of 40
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 06/2017CCKM@uwhealth.org

at 250-500 mL/hr, Intravenous, ONCE, 1 dose Starting when released
Infuse 1000 mL throughout treatment.
Pre-Medications
ondansetron (ZOFRAN) tab 16 mg
16 mg, Oral, ONCE, 1 dose Starting when released
dexamethasone (DECADRON) tab 10 mg
10 mg, Oral, ONCE, 1 dose Starting when released
Treatment Medications
mesna (MESNEX) 1,000 mg in sodium chloride 0.9 % 50 mL bag
1,000 mg (500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
ifosfamide (IFEX) 3,000 mg in sodium chloride 0.9 % 250 mL bag
3,000 mg (1,500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
If prior radiotherapy or chemotherapy give ifosfamide 1200mg/m2 IV once daily for 5 days.
Follow-Up
VERIFY APPOINTMENTS
Verify next day appointment(s) have been scheduled. See follow-up section on Day 1.
Day 3, Cycle 1 – Planned for 6/8/2017
Treatment Plan Information
Treatment Plan Summary
DISEASE: Cervical Cancer (Advanced) Vulvar/Vaginal (Advanced) and Uterine Sarcoma (Adjuvant/Advanced); THERAPY: mesna
500 mg/m2 IV prior ifosfamide on Day 1 through 5; ifosfamide 1500 mg/m2 IV on Day 1 through 5; mesna 500 mg/m2 by mouth 4
hours and 8 hours after the start of ifosfamide; CYCLE LENGTH: 21 days; COURSE: 6 cycles.
Note: If prior radiotherapy or chemotherapy give ifosfamide 1200 mg/m2 IV on Day 1 through 5.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
URINALYSIS, NO MICROSCOPY
Expected-S+1 Approximate, Expires-S+365, Normal, Routine
Treatment Conditions
Verify Labs
Verify pretreatment labs have been obtained and resulted: Urine Heme.
Treatment Parameters
Hold and notify authorizing prescriber for Urine Hemoglobin greater than Trace.
Nursing Procedure, Assessment and Monitoring
Flush Venous Access Device per Guidelines
Order details
sodium chloride flush 0.9% 10 mL injection
Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin lock flush 10 UNIT/ML injection 1-150 units
1-150 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin 100 UNIT/ML lock flush injection 500 units
500 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Implanted port use ONLY to be used when de-accessing port. Flush per VAD guidelines.
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
6/6/2017 5:07:26 PM Page 4 of 40
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 06/2017CCKM@uwhealth.org

Hydration
sodium chloride 0.9 % infusion
at 250-500 mL/hr, Intravenous, ONCE, 1 dose Starting when released
Infuse 1000 mL throughout treatment.
Pre-Medications
ondansetron (ZOFRAN) tab 16 mg
16 mg, Oral, ONCE, 1 dose Starting when released
dexamethasone (DECADRON) tab 10 mg
10 mg, Oral, ONCE, 1 dose Starting when released
Treatment Medications
mesna (MESNEX) 1,000 mg in sodium chloride 0.9 % 50 mL bag
1,000 mg (500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
ifosfamide (IFEX) 3,000 mg in sodium chloride 0.9 % 250 mL bag
3,000 mg (1,500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
If prior radiotherapy or chemotherapy give ifosfamide 1200mg/m2 IV once daily for 5 days.
Follow-Up
VERIFY APPOINTMENTS
Verify next day appointment(s) have been scheduled. See follow-up section on Day 1.
Day 4, Cycle 1 – Planned for 6/9/2017
Treatment Plan Information
Treatment Plan Summary
DISEASE: Cervical Cancer (Advanced) Vulvar/Vaginal (Advanced) and Uterine Sarcoma (Adjuvant/Advanced); THERAPY: mesna
500 mg/m2 IV prior ifosfamide on Day 1 through 5; ifosfamide 1500 mg/m2 IV on Day 1 through 5; mesna 500 mg/m2 by mouth 4
hours and 8 hours after the start of ifosfamide; CYCLE LENGTH: 21 days; COURSE: 6 cycles.
Note: If prior radiotherapy or chemotherapy give ifosfamide 1200 mg/m2 IV on Day 1 through 5.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
URINALYSIS, NO MICROSCOPY
Expected-S+1 Approximate, Expires-S+365, Normal, Routine
Treatment Conditions
Verify Labs
Verify pretreatment labs have been obtained and resulted: Urine Heme.
Treatment Parameters
Hold and notify authorizing prescriber for Urine Hemoglobin greater than Trace.
Nursing Procedure, Assessment and Monitoring
Flush Venous Access Device per Guidelines
Order details
sodium chloride flush 0.9% 10 mL injection
Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin lock flush 10 UNIT/ML injection 1-150 units
1-150 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
6/6/2017 5:07:26 PM Page 5 of 40
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 06/2017CCKM@uwhealth.org

heparin 100 UNIT/ML lock flush injection 500 units
500 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Implanted port use ONLY to be used when de-accessing port. Flush per VAD guidelines.
Hydration
sodium chloride 0.9 % infusion
at 250-500 mL/hr, Intravenous, ONCE, 1 dose Starting when released
Infuse 1000 mL throughout treatment.
Pre-Medications
ondansetron (ZOFRAN) tab 16 mg
16 mg, Oral, ONCE, 1 dose Starting when released
dexamethasone (DECADRON) tab 10 mg
10 mg, Oral, ONCE, 1 dose Starting when released
Treatment Medications
mesna (MESNEX) 1,000 mg in sodium chloride 0.9 % 50 mL bag
1,000 mg (500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
ifosfamide (IFEX) 3,000 mg in sodium chloride 0.9 % 250 mL bag
3,000 mg (1,500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
If prior radiotherapy or chemotherapy give ifosfamide 1200mg/m2 IV once daily for 5 days.
Follow-Up
VERIFY APPOINTMENTS
Verify next day appointment(s) have been scheduled. See follow-up section on Day 1.
Day 5, Cycle 1 – Planned for 6/10/2017
Treatment Plan Information
Treatment Plan Summary
DISEASE: Cervical Cancer (Advanced) Vulvar/Vaginal (Advanced) and Uterine Sarcoma (Adjuvant/Advanced); THERAPY: mesna
500 mg/m2 IV prior ifosfamide on Day 1 through 5; ifosfamide 1500 mg/m2 IV on Day 1 through 5; mesna 500 mg/m2 by mouth 4
hours and 8 hours after the start of ifosfamide; CYCLE LENGTH: 21 days; COURSE: 6 cycles.
Note: If prior radiotherapy or chemotherapy give ifosfamide 1200 mg/m2 IV on Day 1 through 5.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
URINALYSIS, NO MICROSCOPY
Expected-S+1 Approximate, Expires-S+365, Normal, Routine
Treatment Conditions
Verify Labs
Verify pretreatment labs have been obtained and resulted: Urine Heme.
Treatment Parameters
Hold and notify authorizing prescriber for Urine Hemoglobin greater than Trace.
Nursing Procedure, Assessment and Monitoring
Flush Venous Access Device per Guidelines
Order details
sodium chloride flush 0.9% 10 mL injection
Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
6/6/2017 5:07:26 PM Page 6 of 40
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 06/2017CCKM@uwhealth.org

heparin lock flush 10 UNIT/ML injection 1-150 units
1-150 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin 100 UNIT/ML lock flush injection 500 units
500 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Implanted port use ONLY to be used when de-accessing port. Flush per VAD guidelines.
Hydration
sodium chloride 0.9 % infusion
at 250-500 mL/hr, Intravenous, ONCE, 1 dose Starting when released
Infuse 1000 mL throughout treatment.
Pre-Medications
ondansetron (ZOFRAN) tab 16 mg
16 mg, Oral, ONCE, 1 dose Starting when released
dexamethasone (DECADRON) tab 10 mg
10 mg, Oral, ONCE, 1 dose Starting when released
Treatment Medications
mesna (MESNEX) 1,000 mg in sodium chloride 0.9 % 50 mL bag
1,000 mg (500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
ifosfamide (IFEX) 3,000 mg in sodium chloride 0.9 % 250 mL bag
3,000 mg (1,500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
If prior radiotherapy or chemotherapy give ifosfamide 1200mg/m2 IV once daily for 5 days.
Follow-Up
VERIFY APPOINTMENTS
Verify next day appointment(s) have been scheduled. See follow-up section on Day 1.
Day 10 - Lab Only, Cycle 1 – Planned for 6/15/2017
Treatment Plan Information
Treatment Plan Summary
DISEASE: Cervical Cancer (Advanced) Vulvar/Vaginal (Advanced) and Uterine Sarcoma (Adjuvant/Advanced); THERAPY: mesna
500 mg/m2 IV prior ifosfamide on Day 1 through 5; ifosfamide 1500 mg/m2 IV on Day 1 through 5; mesna 500 mg/m2 by mouth 4
hours and 8 hours after the start of ifosfamide; CYCLE LENGTH: 21 days; COURSE: 6 cycles.
Note: If prior radiotherapy or chemotherapy give ifosfamide 1200 mg/m2 IV on Day 1 through 5.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
CBC WITHOUT DIFFERENTIAL
Expected-S+5 Approximate, Expires-S+365, Routine
ABSOLUTE NEUTROPHIL COUNT
Expected-S+5 Approximate, Expires-S+365, Routine
Follow-Up
VERIFY APPOINTMENTS
Verify next day appointment(s) have been scheduled. See follow-up section on Day 1.
Cycle 2 – 6/27/2017 through 7/17/2017 (21 days), Planned
Day 1, Cycle 2 – Planned for 6/27/2017
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
6/6/2017 5:07:26 PM Page 7 of 40
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 06/2017CCKM@uwhealth.org

Treatment Plan Information
Treatment Plan Summary
DISEASE: Cervical Cancer (Advanced) Vulvar/Vaginal (Advanced) and Uterine Sarcoma (Adjuvant/Advanced); THERAPY: mesna
500 mg/m2 IV prior ifosfamide on Day 1 through 5; ifosfamide 1500 mg/m2 IV on Day 1 through 5; mesna 500 mg/m2 by mouth 4
hours and 8 hours after the start of ifosfamide; CYCLE LENGTH: 21 days; COURSE: 6 cycles.
Note: If prior radiotherapy or chemotherapy give ifosfamide 1200 mg/m2 IV on Day 1 through 5.
Consent
Verify Consent
Verify informed consent has been obtained.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
CBC WITHOUT DIFFERENTIAL
Expected-S+17 Approximate, Expires-S+365, Routine
ABSOLUTE NEUTROPHIL COUNT
Expected-S+17 Approximate, Expires-S+365, Routine
ELECTROLYTES
Expected-S+17 Approximate, Expires-S+365, Routine
MAGNESIUM
Expected-S+17 Approximate, Expires-S+365, Routine
GLUCOSE
Expected-S+17 Approximate, Expires-S+365, Routine
BUN
Expected-S+17 Approximate, Expires-S+365, Routine
CREATININE
Expected-S+17 Approximate, Expires-S+365, Routine
URINALYSIS, NO MICROSCOPY
Expected-S+17 Approximate, Expires-S+365, Normal, Routine
Treatment Conditions
Verify Labs
Verify pretreatment labs have been obtained and resulted: CBC, ANC, Urine Heme.
Monitoring Parameters (1)
Hold and notify authorizing prescriber for ANC less than or equal to 1,500/µL or Platelets less than or equal to 100K/µL or Urine
Hemoglobin greater than Trace or Creatinine greater than upper limits of normal.
Nursing Procedure, Assessment and Monitoring
Flush Venous Access Device per Guidelines
Order details
sodium chloride flush 0.9% 10 mL injection
Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin lock flush 10 UNIT/ML injection 1-150 units
1-150 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin 100 UNIT/ML lock flush injection 500 units
500 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Implanted port use ONLY to be used when de-accessing port. Flush per VAD guidelines.
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
6/6/2017 5:07:26 PM Page 8 of 40
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 06/2017CCKM@uwhealth.org

Hydration
sodium chloride 0.9 % infusion
at 250-500 mL/hr, Intravenous, ONCE, 1 dose Starting when released
Infuse 1000 mL throughout treatment.
Pre-Medications
ondansetron (ZOFRAN) tab 16 mg
16 mg, Oral, ONCE, 1 dose Starting when released
dexamethasone (DECADRON) tab 10 mg
10 mg, Oral, ONCE, 1 dose Starting when released
Treatment Medications
mesna (MESNEX) 1,000 mg in sodium chloride 0.9 % 50 mL bag
1,000 mg (500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
ifosfamide (IFEX) 3,000 mg in sodium chloride 0.9 % 250 mL bag
3,000 mg (1,500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
If prior radiotherapy or chemotherapy give ifosfamide 1200mg/m2 IV once daily for 5 days.
Take Home Medications
mesna (MESNEX) 400 MG tab
Take 2.5 tabs by mouth 2 times daily. Take 4 & 8 hours after start of ifosfamide Day 1 thru 5., 1,000 mg (500 mg/m2 × 2 m2
Treatment plan BSA from recorded weight), R-0, 2 X DAILY starting S
Follow-Up
DAY 2 FOLLOW-UP
LABS: Urinalysis without Microscopy; CHEMOTHERAPY ROOM APPOINTMENT: ifosfamide and mesna for 200 minutes.
DAY 3 FOLLOW-UP
LABS: Urinalysis without Microscopy; CHEMOTHERAPY ROOM APPOINTMENT: ifosfamide and mesna for 200 minutes.
DAY 4 FOLLOW-UP
LABS: Urinalysis without Microscopy; CHEMOTHERAPY ROOM APPOINTMENT: ifosfamide and mesna for 200 minutes.
DAY 5 FOLLOW-UP
LABS: Urinalysis without Microscopy; CHEMOTHERAPY ROOM APPOINTMENT: ifosfamide and mesna for 200 minutes.
DAY 10 FOLLOW-UP
LABS: CBC, ANC (DIFF if to be done locally)
DAY 22 FOLLOW-UP
(Day 1 of next cycle) RETURN TO CLINIC for appointment with provider; LABS: CBC, ANC (DIFF if to be done locally), Electrolytes,
Magnesium, Glucose, BUN, Creatinine, Urinalysis without Microscopy; CHEMOTHERAPY ROOM APPOINTMENT: ifosfamide and
mesna for 200 minutes.
Day 2, Cycle 2 – Planned for 6/28/2017
Treatment Plan Information
Treatment Plan Summary
DISEASE: Cervical Cancer (Advanced) Vulvar/Vaginal (Advanced) and Uterine Sarcoma (Adjuvant/Advanced); THERAPY: mesna
500 mg/m2 IV prior ifosfamide on Day 1 through 5; ifosfamide 1500 mg/m2 IV on Day 1 through 5; mesna 500 mg/m2 by mouth 4
hours and 8 hours after the start of ifosfamide; CYCLE LENGTH: 21 days; COURSE: 6 cycles.
Note: If prior radiotherapy or chemotherapy give ifosfamide 1200 mg/m2 IV on Day 1 through 5.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
URINALYSIS, NO MICROSCOPY
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
6/6/2017 5:07:26 PM Page 9 of 40
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 06/2017CCKM@uwhealth.org

Expected-S+1 Approximate, Expires-S+365, Normal, Routine
Treatment Conditions
Verify Labs
Verify pretreatment labs have been obtained and resulted: Urine Heme.
Treatment Parameters
Hold and notify authorizing prescriber for Urine Hemoglobin greater than Trace.
Nursing Procedure, Assessment and Monitoring
Flush Venous Access Device per Guidelines
Order details
sodium chloride flush 0.9% 10 mL injection
Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin lock flush 10 UNIT/ML injection 1-150 units
1-150 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin 100 UNIT/ML lock flush injection 500 units
500 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Implanted port use ONLY to be used when de-accessing port. Flush per VAD guidelines.
Hydration
sodium chloride 0.9 % infusion
at 250-500 mL/hr, Intravenous, ONCE, 1 dose Starting when released
Infuse 1000 mL throughout treatment.
Pre-Medications
ondansetron (ZOFRAN) tab 16 mg
16 mg, Oral, ONCE, 1 dose Starting when released
dexamethasone (DECADRON) tab 10 mg
10 mg, Oral, ONCE, 1 dose Starting when released
Treatment Medications
mesna (MESNEX) 1,000 mg in sodium chloride 0.9 % 50 mL bag
1,000 mg (500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
ifosfamide (IFEX) 3,000 mg in sodium chloride 0.9 % 250 mL bag
3,000 mg (1,500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
If prior radiotherapy or chemotherapy give ifosfamide 1200mg/m2 IV once daily for 5 days.
Follow-Up
VERIFY APPOINTMENTS
Verify next day appointment(s) have been scheduled. See follow-up section on Day 1.
Day 3, Cycle 2 – Planned for 6/29/2017
Treatment Plan Information
Treatment Plan Summary
DISEASE: Cervical Cancer (Advanced) Vulvar/Vaginal (Advanced) and Uterine Sarcoma (Adjuvant/Advanced); THERAPY: mesna
500 mg/m2 IV prior ifosfamide on Day 1 through 5; ifosfamide 1500 mg/m2 IV on Day 1 through 5; mesna 500 mg/m2 by mouth 4
hours and 8 hours after the start of ifosfamide; CYCLE LENGTH: 21 days; COURSE: 6 cycles.
Note: If prior radiotherapy or chemotherapy give ifosfamide 1200 mg/m2 IV on Day 1 through 5.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
6/6/2017 5:07:26 PM Page 10 of 40
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 06/2017CCKM@uwhealth.org

Pre-Labs
URINALYSIS, NO MICROSCOPY
Expected-S+1 Approximate, Expires-S+365, Normal, Routine
Treatment Conditions
Verify Labs
Verify pretreatment labs have been obtained and resulted: Urine Heme.
Treatment Parameters
Hold and notify authorizing prescriber for Urine Hemoglobin greater than Trace.
Nursing Procedure, Assessment and Monitoring
Flush Venous Access Device per Guidelines
Order details
sodium chloride flush 0.9% 10 mL injection
Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin lock flush 10 UNIT/ML injection 1-150 units
1-150 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin 100 UNIT/ML lock flush injection 500 units
500 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Implanted port use ONLY to be used when de-accessing port. Flush per VAD guidelines.
Hydration
sodium chloride 0.9 % infusion
at 250-500 mL/hr, Intravenous, ONCE, 1 dose Starting when released
Infuse 1000 mL throughout treatment.
Pre-Medications
ondansetron (ZOFRAN) tab 16 mg
16 mg, Oral, ONCE, 1 dose Starting when released
dexamethasone (DECADRON) tab 10 mg
10 mg, Oral, ONCE, 1 dose Starting when released
Treatment Medications
mesna (MESNEX) 1,000 mg in sodium chloride 0.9 % 50 mL bag
1,000 mg (500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
ifosfamide (IFEX) 3,000 mg in sodium chloride 0.9 % 250 mL bag
3,000 mg (1,500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
If prior radiotherapy or chemotherapy give ifosfamide 1200mg/m2 IV once daily for 5 days.
Follow-Up
VERIFY APPOINTMENTS
Verify next day appointment(s) have been scheduled. See follow-up section on Day 1.
Day 4, Cycle 2 – Planned for 6/30/2017
Treatment Plan Information
Treatment Plan Summary
DISEASE: Cervical Cancer (Advanced) Vulvar/Vaginal (Advanced) and Uterine Sarcoma (Adjuvant/Advanced); THERAPY: mesna
500 mg/m2 IV prior ifosfamide on Day 1 through 5; ifosfamide 1500 mg/m2 IV on Day 1 through 5; mesna 500 mg/m2 by mouth 4
hours and 8 hours after the start of ifosfamide; CYCLE LENGTH: 21 days; COURSE: 6 cycles.
Note: If prior radiotherapy or chemotherapy give ifosfamide 1200 mg/m2 IV on Day 1 through 5.
IV Access
Insert and Maintain Peripheral IV
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
6/6/2017 5:07:26 PM Page 11 of 40
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 06/2017CCKM@uwhealth.org

CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
URINALYSIS, NO MICROSCOPY
Expected-S+1 Approximate, Expires-S+365, Normal, Routine
Treatment Conditions
Verify Labs
Verify pretreatment labs have been obtained and resulted: Urine Heme.
Treatment Parameters
Hold and notify authorizing prescriber for Urine Hemoglobin greater than Trace.
Nursing Procedure, Assessment and Monitoring
Flush Venous Access Device per Guidelines
Order details
sodium chloride flush 0.9% 10 mL injection
Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin lock flush 10 UNIT/ML injection 1-150 units
1-150 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin 100 UNIT/ML lock flush injection 500 units
500 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Implanted port use ONLY to be used when de-accessing port. Flush per VAD guidelines.
Hydration
sodium chloride 0.9 % infusion
at 250-500 mL/hr, Intravenous, ONCE, 1 dose Starting when released
Infuse 1000 mL throughout treatment.
Pre-Medications
ondansetron (ZOFRAN) tab 16 mg
16 mg, Oral, ONCE, 1 dose Starting when released
dexamethasone (DECADRON) tab 10 mg
10 mg, Oral, ONCE, 1 dose Starting when released
Treatment Medications
mesna (MESNEX) 1,000 mg in sodium chloride 0.9 % 50 mL bag
1,000 mg (500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
ifosfamide (IFEX) 3,000 mg in sodium chloride 0.9 % 250 mL bag
3,000 mg (1,500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
If prior radiotherapy or chemotherapy give ifosfamide 1200mg/m2 IV once daily for 5 days.
Follow-Up
VERIFY APPOINTMENTS
Verify next day appointment(s) have been scheduled. See follow-up section on Day 1.
Day 5, Cycle 2 – Planned for 7/1/2017
Treatment Plan Information
Treatment Plan Summary
DISEASE: Cervical Cancer (Advanced) Vulvar/Vaginal (Advanced) and Uterine Sarcoma (Adjuvant/Advanced); THERAPY: mesna
500 mg/m2 IV prior ifosfamide on Day 1 through 5; ifosfamide 1500 mg/m2 IV on Day 1 through 5; mesna 500 mg/m2 by mouth 4
hours and 8 hours after the start of ifosfamide; CYCLE LENGTH: 21 days; COURSE: 6 cycles.
Note: If prior radiotherapy or chemotherapy give ifosfamide 1200 mg/m2 IV on Day 1 through 5.
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
6/6/2017 5:07:26 PM Page 12 of 40
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 06/2017CCKM@uwhealth.org

IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
URINALYSIS, NO MICROSCOPY
Expected-S+1 Approximate, Expires-S+365, Normal, Routine
Treatment Conditions
Verify Labs
Verify pretreatment labs have been obtained and resulted: Urine Heme.
Treatment Parameters
Hold and notify authorizing prescriber for Urine Hemoglobin greater than Trace.
Nursing Procedure, Assessment and Monitoring
Flush Venous Access Device per Guidelines
Order details
sodium chloride flush 0.9% 10 mL injection
Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin lock flush 10 UNIT/ML injection 1-150 units
1-150 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin 100 UNIT/ML lock flush injection 500 units
500 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Implanted port use ONLY to be used when de-accessing port. Flush per VAD guidelines.
Hydration
sodium chloride 0.9 % infusion
at 250-500 mL/hr, Intravenous, ONCE, 1 dose Starting when released
Infuse 1000 mL throughout treatment.
Pre-Medications
ondansetron (ZOFRAN) tab 16 mg
16 mg, Oral, ONCE, 1 dose Starting when released
dexamethasone (DECADRON) tab 10 mg
10 mg, Oral, ONCE, 1 dose Starting when released
Treatment Medications
mesna (MESNEX) 1,000 mg in sodium chloride 0.9 % 50 mL bag
1,000 mg (500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
ifosfamide (IFEX) 3,000 mg in sodium chloride 0.9 % 250 mL bag
3,000 mg (1,500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
If prior radiotherapy or chemotherapy give ifosfamide 1200mg/m2 IV once daily for 5 days.
Follow-Up
VERIFY APPOINTMENTS
Verify next day appointment(s) have been scheduled. See follow-up section on Day 1.
Day 10 - Lab Only, Cycle 2 – Planned for 7/6/2017
Treatment Plan Information
Treatment Plan Summary
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
6/6/2017 5:07:26 PM Page 13 of 40
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 06/2017CCKM@uwhealth.org

DISEASE: Cervical Cancer (Advanced) Vulvar/Vaginal (Advanced) and Uterine Sarcoma (Adjuvant/Advanced); THERAPY: mesna
500 mg/m2 IV prior ifosfamide on Day 1 through 5; ifosfamide 1500 mg/m2 IV on Day 1 through 5; mesna 500 mg/m2 by mouth 4
hours and 8 hours after the start of ifosfamide; CYCLE LENGTH: 21 days; COURSE: 6 cycles.
Note: If prior radiotherapy or chemotherapy give ifosfamide 1200 mg/m2 IV on Day 1 through 5.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
CBC WITHOUT DIFFERENTIAL
Expected-S+5 Approximate, Expires-S+365, Routine
ABSOLUTE NEUTROPHIL COUNT
Expected-S+5 Approximate, Expires-S+365, Routine
Follow-Up
VERIFY APPOINTMENTS
Verify next day appointment(s) have been scheduled. See follow-up section on Day 1.
Cycle 3 – 7/18/2017 through 8/7/2017 (21 days), Planned
Day 1, Cycle 3 – Planned for 7/18/2017
Treatment Plan Information
Treatment Plan Summary
DISEASE: Cervical Cancer (Advanced) Vulvar/Vaginal (Advanced) and Uterine Sarcoma (Adjuvant/Advanced); THERAPY: mesna
500 mg/m2 IV prior ifosfamide on Day 1 through 5; ifosfamide 1500 mg/m2 IV on Day 1 through 5; mesna 500 mg/m2 by mouth 4
hours and 8 hours after the start of ifosfamide; CYCLE LENGTH: 21 days; COURSE: 6 cycles.
Note: If prior radiotherapy or chemotherapy give ifosfamide 1200 mg/m2 IV on Day 1 through 5.
Consent
Verify Consent
Verify informed consent has been obtained.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
CBC WITHOUT DIFFERENTIAL
Expected-S+17 Approximate, Expires-S+365, Routine
ABSOLUTE NEUTROPHIL COUNT
Expected-S+17 Approximate, Expires-S+365, Routine
ELECTROLYTES
Expected-S+17 Approximate, Expires-S+365, Routine
MAGNESIUM
Expected-S+17 Approximate, Expires-S+365, Routine
GLUCOSE
Expected-S+17 Approximate, Expires-S+365, Routine
BUN
Expected-S+17 Approximate, Expires-S+365, Routine
CREATININE
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
6/6/2017 5:07:26 PM Page 14 of 40
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 06/2017CCKM@uwhealth.org

Expected-S+17 Approximate, Expires-S+365, Routine
URINALYSIS, NO MICROSCOPY
Expected-S+17 Approximate, Expires-S+365, Normal, Routine
Treatment Conditions
Verify Labs
Verify pretreatment labs have been obtained and resulted: CBC, ANC, Urine Heme.
Monitoring Parameters (1)
Hold and notify authorizing prescriber for ANC less than or equal to 1,500/µL or Platelets less than or equal to 100K/µL or Urine
Hemoglobin greater than Trace or Creatinine greater than upper limits of normal.
Nursing Procedure, Assessment and Monitoring
Flush Venous Access Device per Guidelines
Order details
sodium chloride flush 0.9% 10 mL injection
Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin lock flush 10 UNIT/ML injection 1-150 units
1-150 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin 100 UNIT/ML lock flush injection 500 units
500 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Implanted port use ONLY to be used when de-accessing port. Flush per VAD guidelines.
Hydration
sodium chloride 0.9 % infusion
at 250-500 mL/hr, Intravenous, ONCE, 1 dose Starting when released
Infuse 1000 mL throughout treatment.
Pre-Medications
ondansetron (ZOFRAN) tab 16 mg
16 mg, Oral, ONCE, 1 dose Starting when released
dexamethasone (DECADRON) tab 10 mg
10 mg, Oral, ONCE, 1 dose Starting when released
Treatment Medications
mesna (MESNEX) 1,000 mg in sodium chloride 0.9 % 50 mL bag
1,000 mg (500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
ifosfamide (IFEX) 3,000 mg in sodium chloride 0.9 % 250 mL bag
3,000 mg (1,500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
If prior radiotherapy or chemotherapy give ifosfamide 1200mg/m2 IV once daily for 5 days.
Take Home Medications
mesna (MESNEX) 400 MG tab
Take 2.5 tabs by mouth 2 times daily. Take 4 & 8 hours after start of ifosfamide Day 1 thru 5., 1,000 mg (500 mg/m2 × 2 m2
Treatment plan BSA from recorded weight), R-0, 2 X DAILY starting S
Follow-Up
DAY 2 FOLLOW-UP
LABS: Urinalysis without Microscopy; CHEMOTHERAPY ROOM APPOINTMENT: ifosfamide and mesna for 200 minutes.
DAY 3 FOLLOW-UP
LABS: Urinalysis without Microscopy; CHEMOTHERAPY ROOM APPOINTMENT: ifosfamide and mesna for 200 minutes.
DAY 4 FOLLOW-UP
LABS: Urinalysis without Microscopy; CHEMOTHERAPY ROOM APPOINTMENT: ifosfamide and mesna for 200 minutes.
DAY 5 FOLLOW-UP
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
6/6/2017 5:07:26 PM Page 15 of 40
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 06/2017CCKM@uwhealth.org

LABS: Urinalysis without Microscopy; CHEMOTHERAPY ROOM APPOINTMENT: ifosfamide and mesna for 200 minutes.
DAY 10 FOLLOW-UP
LABS: CBC, ANC (DIFF if to be done locally)
DAY 22 FOLLOW-UP
(Day 1 of next cycle) RETURN TO CLINIC for appointment with provider; LABS: CBC, ANC (DIFF if to be done locally), Electrolytes,
Magnesium, Glucose, BUN, Creatinine, Urinalysis without Microscopy; CHEMOTHERAPY ROOM APPOINTMENT: ifosfamide and
mesna for 200 minutes.
Day 2, Cycle 3 – Planned for 7/19/2017
Treatment Plan Information
Treatment Plan Summary
DISEASE: Cervical Cancer (Advanced) Vulvar/Vaginal (Advanced) and Uterine Sarcoma (Adjuvant/Advanced); THERAPY: mesna
500 mg/m2 IV prior ifosfamide on Day 1 through 5; ifosfamide 1500 mg/m2 IV on Day 1 through 5; mesna 500 mg/m2 by mouth 4
hours and 8 hours after the start of ifosfamide; CYCLE LENGTH: 21 days; COURSE: 6 cycles.
Note: If prior radiotherapy or chemotherapy give ifosfamide 1200 mg/m2 IV on Day 1 through 5.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
URINALYSIS, NO MICROSCOPY
Expected-S+1 Approximate, Expires-S+365, Normal, Routine
Treatment Conditions
Verify Labs
Verify pretreatment labs have been obtained and resulted: Urine Heme.
Treatment Parameters
Hold and notify authorizing prescriber for Urine Hemoglobin greater than Trace.
Nursing Procedure, Assessment and Monitoring
Flush Venous Access Device per Guidelines
Order details
sodium chloride flush 0.9% 10 mL injection
Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin lock flush 10 UNIT/ML injection 1-150 units
1-150 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin 100 UNIT/ML lock flush injection 500 units
500 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Implanted port use ONLY to be used when de-accessing port. Flush per VAD guidelines.
Hydration
sodium chloride 0.9 % infusion
at 250-500 mL/hr, Intravenous, ONCE, 1 dose Starting when released
Infuse 1000 mL throughout treatment.
Pre-Medications
ondansetron (ZOFRAN) tab 16 mg
16 mg, Oral, ONCE, 1 dose Starting when released
dexamethasone (DECADRON) tab 10 mg
10 mg, Oral, ONCE, 1 dose Starting when released
Treatment Medications
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
6/6/2017 5:07:26 PM Page 16 of 40
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 06/2017CCKM@uwhealth.org

mesna (MESNEX) 1,000 mg in sodium chloride 0.9 % 50 mL bag
1,000 mg (500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
ifosfamide (IFEX) 3,000 mg in sodium chloride 0.9 % 250 mL bag
3,000 mg (1,500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
If prior radiotherapy or chemotherapy give ifosfamide 1200mg/m2 IV once daily for 5 days.
Follow-Up
VERIFY APPOINTMENTS
Verify next day appointment(s) have been scheduled. See follow-up section on Day 1.
Day 3, Cycle 3 – Planned for 7/20/2017
Treatment Plan Information
Treatment Plan Summary
DISEASE: Cervical Cancer (Advanced) Vulvar/Vaginal (Advanced) and Uterine Sarcoma (Adjuvant/Advanced); THERAPY: mesna
500 mg/m2 IV prior ifosfamide on Day 1 through 5; ifosfamide 1500 mg/m2 IV on Day 1 through 5; mesna 500 mg/m2 by mouth 4
hours and 8 hours after the start of ifosfamide; CYCLE LENGTH: 21 days; COURSE: 6 cycles.
Note: If prior radiotherapy or chemotherapy give ifosfamide 1200 mg/m2 IV on Day 1 through 5.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
URINALYSIS, NO MICROSCOPY
Expected-S+1 Approximate, Expires-S+365, Normal, Routine
Treatment Conditions
Verify Labs
Verify pretreatment labs have been obtained and resulted: Urine Heme.
Treatment Parameters
Hold and notify authorizing prescriber for Urine Hemoglobin greater than Trace.
Nursing Procedure, Assessment and Monitoring
Flush Venous Access Device per Guidelines
Order details
sodium chloride flush 0.9% 10 mL injection
Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin lock flush 10 UNIT/ML injection 1-150 units
1-150 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin 100 UNIT/ML lock flush injection 500 units
500 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Implanted port use ONLY to be used when de-accessing port. Flush per VAD guidelines.
Hydration
sodium chloride 0.9 % infusion
at 250-500 mL/hr, Intravenous, ONCE, 1 dose Starting when released
Infuse 1000 mL throughout treatment.
Pre-Medications
ondansetron (ZOFRAN) tab 16 mg
16 mg, Oral, ONCE, 1 dose Starting when released
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
6/6/2017 5:07:26 PM Page 17 of 40
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 06/2017CCKM@uwhealth.org

dexamethasone (DECADRON) tab 10 mg
10 mg, Oral, ONCE, 1 dose Starting when released
Treatment Medications
mesna (MESNEX) 1,000 mg in sodium chloride 0.9 % 50 mL bag
1,000 mg (500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
ifosfamide (IFEX) 3,000 mg in sodium chloride 0.9 % 250 mL bag
3,000 mg (1,500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
If prior radiotherapy or chemotherapy give ifosfamide 1200mg/m2 IV once daily for 5 days.
Follow-Up
VERIFY APPOINTMENTS
Verify next day appointment(s) have been scheduled. See follow-up section on Day 1.
Day 4, Cycle 3 – Planned for 7/21/2017
Treatment Plan Information
Treatment Plan Summary
DISEASE: Cervical Cancer (Advanced) Vulvar/Vaginal (Advanced) and Uterine Sarcoma (Adjuvant/Advanced); THERAPY: mesna
500 mg/m2 IV prior ifosfamide on Day 1 through 5; ifosfamide 1500 mg/m2 IV on Day 1 through 5; mesna 500 mg/m2 by mouth 4
hours and 8 hours after the start of ifosfamide; CYCLE LENGTH: 21 days; COURSE: 6 cycles.
Note: If prior radiotherapy or chemotherapy give ifosfamide 1200 mg/m2 IV on Day 1 through 5.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
URINALYSIS, NO MICROSCOPY
Expected-S+1 Approximate, Expires-S+365, Normal, Routine
Treatment Conditions
Verify Labs
Verify pretreatment labs have been obtained and resulted: Urine Heme.
Treatment Parameters
Hold and notify authorizing prescriber for Urine Hemoglobin greater than Trace.
Nursing Procedure, Assessment and Monitoring
Flush Venous Access Device per Guidelines
Order details
sodium chloride flush 0.9% 10 mL injection
Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin lock flush 10 UNIT/ML injection 1-150 units
1-150 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin 100 UNIT/ML lock flush injection 500 units
500 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Implanted port use ONLY to be used when de-accessing port. Flush per VAD guidelines.
Hydration
sodium chloride 0.9 % infusion
at 250-500 mL/hr, Intravenous, ONCE, 1 dose Starting when released
Infuse 1000 mL throughout treatment.
Pre-Medications
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
6/6/2017 5:07:26 PM Page 18 of 40
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 06/2017CCKM@uwhealth.org

ondansetron (ZOFRAN) tab 16 mg
16 mg, Oral, ONCE, 1 dose Starting when released
dexamethasone (DECADRON) tab 10 mg
10 mg, Oral, ONCE, 1 dose Starting when released
Treatment Medications
mesna (MESNEX) 1,000 mg in sodium chloride 0.9 % 50 mL bag
1,000 mg (500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
ifosfamide (IFEX) 3,000 mg in sodium chloride 0.9 % 250 mL bag
3,000 mg (1,500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
If prior radiotherapy or chemotherapy give ifosfamide 1200mg/m2 IV once daily for 5 days.
Follow-Up
VERIFY APPOINTMENTS
Verify next day appointment(s) have been scheduled. See follow-up section on Day 1.
Day 5, Cycle 3 – Planned for 7/22/2017
Treatment Plan Information
Treatment Plan Summary
DISEASE: Cervical Cancer (Advanced) Vulvar/Vaginal (Advanced) and Uterine Sarcoma (Adjuvant/Advanced); THERAPY: mesna
500 mg/m2 IV prior ifosfamide on Day 1 through 5; ifosfamide 1500 mg/m2 IV on Day 1 through 5; mesna 500 mg/m2 by mouth 4
hours and 8 hours after the start of ifosfamide; CYCLE LENGTH: 21 days; COURSE: 6 cycles.
Note: If prior radiotherapy or chemotherapy give ifosfamide 1200 mg/m2 IV on Day 1 through 5.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
URINALYSIS, NO MICROSCOPY
Expected-S+1 Approximate, Expires-S+365, Normal, Routine
Treatment Conditions
Verify Labs
Verify pretreatment labs have been obtained and resulted: Urine Heme.
Treatment Parameters
Hold and notify authorizing prescriber for Urine Hemoglobin greater than Trace.
Nursing Procedure, Assessment and Monitoring
Flush Venous Access Device per Guidelines
Order details
sodium chloride flush 0.9% 10 mL injection
Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin lock flush 10 UNIT/ML injection 1-150 units
1-150 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin 100 UNIT/ML lock flush injection 500 units
500 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Implanted port use ONLY to be used when de-accessing port. Flush per VAD guidelines.
Hydration
sodium chloride 0.9 % infusion
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
6/6/2017 5:07:26 PM Page 19 of 40
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 06/2017CCKM@uwhealth.org

at 250-500 mL/hr, Intravenous, ONCE, 1 dose Starting when released
Infuse 1000 mL throughout treatment.
Pre-Medications
ondansetron (ZOFRAN) tab 16 mg
16 mg, Oral, ONCE, 1 dose Starting when released
dexamethasone (DECADRON) tab 10 mg
10 mg, Oral, ONCE, 1 dose Starting when released
Treatment Medications
mesna (MESNEX) 1,000 mg in sodium chloride 0.9 % 50 mL bag
1,000 mg (500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
ifosfamide (IFEX) 3,000 mg in sodium chloride 0.9 % 250 mL bag
3,000 mg (1,500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
If prior radiotherapy or chemotherapy give ifosfamide 1200mg/m2 IV once daily for 5 days.
Follow-Up
VERIFY APPOINTMENTS
Verify next day appointment(s) have been scheduled. See follow-up section on Day 1.
Day 10 - Lab Only, Cycle 3 – Planned for 7/27/2017
Treatment Plan Information
Treatment Plan Summary
DISEASE: Cervical Cancer (Advanced) Vulvar/Vaginal (Advanced) and Uterine Sarcoma (Adjuvant/Advanced); THERAPY: mesna
500 mg/m2 IV prior ifosfamide on Day 1 through 5; ifosfamide 1500 mg/m2 IV on Day 1 through 5; mesna 500 mg/m2 by mouth 4
hours and 8 hours after the start of ifosfamide; CYCLE LENGTH: 21 days; COURSE: 6 cycles.
Note: If prior radiotherapy or chemotherapy give ifosfamide 1200 mg/m2 IV on Day 1 through 5.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
CBC WITHOUT DIFFERENTIAL
Expected-S+5 Approximate, Expires-S+365, Routine
ABSOLUTE NEUTROPHIL COUNT
Expected-S+5 Approximate, Expires-S+365, Routine
Follow-Up
VERIFY APPOINTMENTS
Verify next day appointment(s) have been scheduled. See follow-up section on Day 1.
Cycle 4 – 8/8/2017 through 8/28/2017 (21 days), Planned
Day 1, Cycle 4 – Planned for 8/8/2017
Treatment Plan Information
Treatment Plan Summary
DISEASE: Cervical Cancer (Advanced) Vulvar/Vaginal (Advanced) and Uterine Sarcoma (Adjuvant/Advanced); THERAPY: mesna
500 mg/m2 IV prior ifosfamide on Day 1 through 5; ifosfamide 1500 mg/m2 IV on Day 1 through 5; mesna 500 mg/m2 by mouth 4
hours and 8 hours after the start of ifosfamide; CYCLE LENGTH: 21 days; COURSE: 6 cycles.
Note: If prior radiotherapy or chemotherapy give ifosfamide 1200 mg/m2 IV on Day 1 through 5.
Consent
Verify Consent
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
6/6/2017 5:07:26 PM Page 20 of 40
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 06/2017CCKM@uwhealth.org

Verify informed consent has been obtained.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
CBC WITHOUT DIFFERENTIAL
Expected-S+17 Approximate, Expires-S+365, Routine
ABSOLUTE NEUTROPHIL COUNT
Expected-S+17 Approximate, Expires-S+365, Routine
ELECTROLYTES
Expected-S+17 Approximate, Expires-S+365, Routine
MAGNESIUM
Expected-S+17 Approximate, Expires-S+365, Routine
GLUCOSE
Expected-S+17 Approximate, Expires-S+365, Routine
BUN
Expected-S+17 Approximate, Expires-S+365, Routine
CREATININE
Expected-S+17 Approximate, Expires-S+365, Routine
URINALYSIS, NO MICROSCOPY
Expected-S+17 Approximate, Expires-S+365, Normal, Routine
Treatment Conditions
Verify Labs
Verify pretreatment labs have been obtained and resulted: CBC, ANC, Urine Heme.
Monitoring Parameters (1)
Hold and notify authorizing prescriber for ANC less than or equal to 1,500/µL or Platelets less than or equal to 100K/µL or Urine
Hemoglobin greater than Trace or Creatinine greater than upper limits of normal.
Nursing Procedure, Assessment and Monitoring
Flush Venous Access Device per Guidelines
Order details
sodium chloride flush 0.9% 10 mL injection
Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin lock flush 10 UNIT/ML injection 1-150 units
1-150 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin 100 UNIT/ML lock flush injection 500 units
500 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Implanted port use ONLY to be used when de-accessing port. Flush per VAD guidelines.
Hydration
sodium chloride 0.9 % infusion
at 250-500 mL/hr, Intravenous, ONCE, 1 dose Starting when released
Infuse 1000 mL throughout treatment.
Pre-Medications
ondansetron (ZOFRAN) tab 16 mg
16 mg, Oral, ONCE, 1 dose Starting when released
dexamethasone (DECADRON) tab 10 mg
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
6/6/2017 5:07:26 PM Page 21 of 40
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 06/2017CCKM@uwhealth.org

10 mg, Oral, ONCE, 1 dose Starting when released
Treatment Medications
mesna (MESNEX) 1,000 mg in sodium chloride 0.9 % 50 mL bag
1,000 mg (500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
ifosfamide (IFEX) 3,000 mg in sodium chloride 0.9 % 250 mL bag
3,000 mg (1,500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
If prior radiotherapy or chemotherapy give ifosfamide 1200mg/m2 IV once daily for 5 days.
Take Home Medications
mesna (MESNEX) 400 MG tab
Take 2.5 tabs by mouth 2 times daily. Take 4 & 8 hours after start of ifosfamide Day 1 thru 5., 1,000 mg (500 mg/m2 × 2 m2
Treatment plan BSA from recorded weight), R-0, 2 X DAILY starting S
Follow-Up
DAY 2 FOLLOW-UP
LABS: Urinalysis without Microscopy; CHEMOTHERAPY ROOM APPOINTMENT: ifosfamide and mesna for 200 minutes.
DAY 3 FOLLOW-UP
LABS: Urinalysis without Microscopy; CHEMOTHERAPY ROOM APPOINTMENT: ifosfamide and mesna for 200 minutes.
DAY 4 FOLLOW-UP
LABS: Urinalysis without Microscopy; CHEMOTHERAPY ROOM APPOINTMENT: ifosfamide and mesna for 200 minutes.
DAY 5 FOLLOW-UP
LABS: Urinalysis without Microscopy; CHEMOTHERAPY ROOM APPOINTMENT: ifosfamide and mesna for 200 minutes.
DAY 10 FOLLOW-UP
LABS: CBC, ANC (DIFF if to be done locally)
DAY 22 FOLLOW-UP
(Day 1 of next cycle) RETURN TO CLINIC for appointment with provider; LABS: CBC, ANC (DIFF if to be done locally), Electrolytes,
Magnesium, Glucose, BUN, Creatinine, Urinalysis without Microscopy; CHEMOTHERAPY ROOM APPOINTMENT: ifosfamide and
mesna for 200 minutes.
Day 2, Cycle 4 – Planned for 8/9/2017
Treatment Plan Information
Treatment Plan Summary
DISEASE: Cervical Cancer (Advanced) Vulvar/Vaginal (Advanced) and Uterine Sarcoma (Adjuvant/Advanced); THERAPY: mesna
500 mg/m2 IV prior ifosfamide on Day 1 through 5; ifosfamide 1500 mg/m2 IV on Day 1 through 5; mesna 500 mg/m2 by mouth 4
hours and 8 hours after the start of ifosfamide; CYCLE LENGTH: 21 days; COURSE: 6 cycles.
Note: If prior radiotherapy or chemotherapy give ifosfamide 1200 mg/m2 IV on Day 1 through 5.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
URINALYSIS, NO MICROSCOPY
Expected-S+1 Approximate, Expires-S+365, Normal, Routine
Treatment Conditions
Verify Labs
Verify pretreatment labs have been obtained and resulted: Urine Heme.
Treatment Parameters
Hold and notify authorizing prescriber for Urine Hemoglobin greater than Trace.
Nursing Procedure, Assessment and Monitoring
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
6/6/2017 5:07:26 PM Page 22 of 40
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 06/2017CCKM@uwhealth.org

Flush Venous Access Device per Guidelines
Order details
sodium chloride flush 0.9% 10 mL injection
Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin lock flush 10 UNIT/ML injection 1-150 units
1-150 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin 100 UNIT/ML lock flush injection 500 units
500 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Implanted port use ONLY to be used when de-accessing port. Flush per VAD guidelines.
Hydration
sodium chloride 0.9 % infusion
at 250-500 mL/hr, Intravenous, ONCE, 1 dose Starting when released
Infuse 1000 mL throughout treatment.
Pre-Medications
ondansetron (ZOFRAN) tab 16 mg
16 mg, Oral, ONCE, 1 dose Starting when released
dexamethasone (DECADRON) tab 10 mg
10 mg, Oral, ONCE, 1 dose Starting when released
Treatment Medications
mesna (MESNEX) 1,000 mg in sodium chloride 0.9 % 50 mL bag
1,000 mg (500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
ifosfamide (IFEX) 3,000 mg in sodium chloride 0.9 % 250 mL bag
3,000 mg (1,500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
If prior radiotherapy or chemotherapy give ifosfamide 1200mg/m2 IV once daily for 5 days.
Follow-Up
VERIFY APPOINTMENTS
Verify next day appointment(s) have been scheduled. See follow-up section on Day 1.
Day 3, Cycle 4 – Planned for 8/10/2017
Treatment Plan Information
Treatment Plan Summary
DISEASE: Cervical Cancer (Advanced) Vulvar/Vaginal (Advanced) and Uterine Sarcoma (Adjuvant/Advanced); THERAPY: mesna
500 mg/m2 IV prior ifosfamide on Day 1 through 5; ifosfamide 1500 mg/m2 IV on Day 1 through 5; mesna 500 mg/m2 by mouth 4
hours and 8 hours after the start of ifosfamide; CYCLE LENGTH: 21 days; COURSE: 6 cycles.
Note: If prior radiotherapy or chemotherapy give ifosfamide 1200 mg/m2 IV on Day 1 through 5.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
URINALYSIS, NO MICROSCOPY
Expected-S+1 Approximate, Expires-S+365, Normal, Routine
Treatment Conditions
Verify Labs
Verify pretreatment labs have been obtained and resulted: Urine Heme.
Treatment Parameters
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
6/6/2017 5:07:26 PM Page 23 of 40
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 06/2017CCKM@uwhealth.org

Hold and notify authorizing prescriber for Urine Hemoglobin greater than Trace.
Nursing Procedure, Assessment and Monitoring
Flush Venous Access Device per Guidelines
Order details
sodium chloride flush 0.9% 10 mL injection
Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin lock flush 10 UNIT/ML injection 1-150 units
1-150 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin 100 UNIT/ML lock flush injection 500 units
500 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Implanted port use ONLY to be used when de-accessing port. Flush per VAD guidelines.
Hydration
sodium chloride 0.9 % infusion
at 250-500 mL/hr, Intravenous, ONCE, 1 dose Starting when released
Infuse 1000 mL throughout treatment.
Pre-Medications
ondansetron (ZOFRAN) tab 16 mg
16 mg, Oral, ONCE, 1 dose Starting when released
dexamethasone (DECADRON) tab 10 mg
10 mg, Oral, ONCE, 1 dose Starting when released
Treatment Medications
mesna (MESNEX) 1,000 mg in sodium chloride 0.9 % 50 mL bag
1,000 mg (500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
ifosfamide (IFEX) 3,000 mg in sodium chloride 0.9 % 250 mL bag
3,000 mg (1,500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
If prior radiotherapy or chemotherapy give ifosfamide 1200mg/m2 IV once daily for 5 days.
Follow-Up
VERIFY APPOINTMENTS
Verify next day appointment(s) have been scheduled. See follow-up section on Day 1.
Day 4, Cycle 4 – Planned for 8/11/2017
Treatment Plan Information
Treatment Plan Summary
DISEASE: Cervical Cancer (Advanced) Vulvar/Vaginal (Advanced) and Uterine Sarcoma (Adjuvant/Advanced); THERAPY: mesna
500 mg/m2 IV prior ifosfamide on Day 1 through 5; ifosfamide 1500 mg/m2 IV on Day 1 through 5; mesna 500 mg/m2 by mouth 4
hours and 8 hours after the start of ifosfamide; CYCLE LENGTH: 21 days; COURSE: 6 cycles.
Note: If prior radiotherapy or chemotherapy give ifosfamide 1200 mg/m2 IV on Day 1 through 5.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
URINALYSIS, NO MICROSCOPY
Expected-S+1 Approximate, Expires-S+365, Normal, Routine
Treatment Conditions
Verify Labs
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
6/6/2017 5:07:26 PM Page 24 of 40
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 06/2017CCKM@uwhealth.org

Verify pretreatment labs have been obtained and resulted: Urine Heme.
Treatment Parameters
Hold and notify authorizing prescriber for Urine Hemoglobin greater than Trace.
Nursing Procedure, Assessment and Monitoring
Flush Venous Access Device per Guidelines
Order details
sodium chloride flush 0.9% 10 mL injection
Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin lock flush 10 UNIT/ML injection 1-150 units
1-150 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin 100 UNIT/ML lock flush injection 500 units
500 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Implanted port use ONLY to be used when de-accessing port. Flush per VAD guidelines.
Hydration
sodium chloride 0.9 % infusion
at 250-500 mL/hr, Intravenous, ONCE, 1 dose Starting when released
Infuse 1000 mL throughout treatment.
Pre-Medications
ondansetron (ZOFRAN) tab 16 mg
16 mg, Oral, ONCE, 1 dose Starting when released
dexamethasone (DECADRON) tab 10 mg
10 mg, Oral, ONCE, 1 dose Starting when released
Treatment Medications
mesna (MESNEX) 1,000 mg in sodium chloride 0.9 % 50 mL bag
1,000 mg (500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
ifosfamide (IFEX) 3,000 mg in sodium chloride 0.9 % 250 mL bag
3,000 mg (1,500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
If prior radiotherapy or chemotherapy give ifosfamide 1200mg/m2 IV once daily for 5 days.
Follow-Up
VERIFY APPOINTMENTS
Verify next day appointment(s) have been scheduled. See follow-up section on Day 1.
Day 5, Cycle 4 – Planned for 8/12/2017
Treatment Plan Information
Treatment Plan Summary
DISEASE: Cervical Cancer (Advanced) Vulvar/Vaginal (Advanced) and Uterine Sarcoma (Adjuvant/Advanced); THERAPY: mesna
500 mg/m2 IV prior ifosfamide on Day 1 through 5; ifosfamide 1500 mg/m2 IV on Day 1 through 5; mesna 500 mg/m2 by mouth 4
hours and 8 hours after the start of ifosfamide; CYCLE LENGTH: 21 days; COURSE: 6 cycles.
Note: If prior radiotherapy or chemotherapy give ifosfamide 1200 mg/m2 IV on Day 1 through 5.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
URINALYSIS, NO MICROSCOPY
Expected-S+1 Approximate, Expires-S+365, Normal, Routine
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
6/6/2017 5:07:26 PM Page 25 of 40
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 06/2017CCKM@uwhealth.org

Treatment Conditions
Verify Labs
Verify pretreatment labs have been obtained and resulted: Urine Heme.
Treatment Parameters
Hold and notify authorizing prescriber for Urine Hemoglobin greater than Trace.
Nursing Procedure, Assessment and Monitoring
Flush Venous Access Device per Guidelines
Order details
sodium chloride flush 0.9% 10 mL injection
Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin lock flush 10 UNIT/ML injection 1-150 units
1-150 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin 100 UNIT/ML lock flush injection 500 units
500 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Implanted port use ONLY to be used when de-accessing port. Flush per VAD guidelines.
Hydration
sodium chloride 0.9 % infusion
at 250-500 mL/hr, Intravenous, ONCE, 1 dose Starting when released
Infuse 1000 mL throughout treatment.
Pre-Medications
ondansetron (ZOFRAN) tab 16 mg
16 mg, Oral, ONCE, 1 dose Starting when released
dexamethasone (DECADRON) tab 10 mg
10 mg, Oral, ONCE, 1 dose Starting when released
Treatment Medications
mesna (MESNEX) 1,000 mg in sodium chloride 0.9 % 50 mL bag
1,000 mg (500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
ifosfamide (IFEX) 3,000 mg in sodium chloride 0.9 % 250 mL bag
3,000 mg (1,500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
If prior radiotherapy or chemotherapy give ifosfamide 1200mg/m2 IV once daily for 5 days.
Follow-Up
VERIFY APPOINTMENTS
Verify next day appointment(s) have been scheduled. See follow-up section on Day 1.
Day 10 - Lab Only, Cycle 4 – Planned for 8/17/2017
Treatment Plan Information
Treatment Plan Summary
DISEASE: Cervical Cancer (Advanced) Vulvar/Vaginal (Advanced) and Uterine Sarcoma (Adjuvant/Advanced); THERAPY: mesna
500 mg/m2 IV prior ifosfamide on Day 1 through 5; ifosfamide 1500 mg/m2 IV on Day 1 through 5; mesna 500 mg/m2 by mouth 4
hours and 8 hours after the start of ifosfamide; CYCLE LENGTH: 21 days; COURSE: 6 cycles.
Note: If prior radiotherapy or chemotherapy give ifosfamide 1200 mg/m2 IV on Day 1 through 5.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
6/6/2017 5:07:26 PM Page 26 of 40
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 06/2017CCKM@uwhealth.org

CBC WITHOUT DIFFERENTIAL
Expected-S+5 Approximate, Expires-S+365, Routine
ABSOLUTE NEUTROPHIL COUNT
Expected-S+5 Approximate, Expires-S+365, Routine
Follow-Up
VERIFY APPOINTMENTS
Verify next day appointment(s) have been scheduled. See follow-up section on Day 1.
Cycle 5 – 8/29/2017 through 9/18/2017 (21 days), Planned
Day 1, Cycle 5 – Planned for 8/29/2017
Treatment Plan Information
Treatment Plan Summary
DISEASE: Cervical Cancer (Advanced) Vulvar/Vaginal (Advanced) and Uterine Sarcoma (Adjuvant/Advanced); THERAPY: mesna
500 mg/m2 IV prior ifosfamide on Day 1 through 5; ifosfamide 1500 mg/m2 IV on Day 1 through 5; mesna 500 mg/m2 by mouth 4
hours and 8 hours after the start of ifosfamide; CYCLE LENGTH: 21 days; COURSE: 6 cycles.
Note: If prior radiotherapy or chemotherapy give ifosfamide 1200 mg/m2 IV on Day 1 through 5.
Consent
Verify Consent
Verify informed consent has been obtained.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
CBC WITHOUT DIFFERENTIAL
Expected-S+17 Approximate, Expires-S+365, Routine
ABSOLUTE NEUTROPHIL COUNT
Expected-S+17 Approximate, Expires-S+365, Routine
ELECTROLYTES
Expected-S+17 Approximate, Expires-S+365, Routine
MAGNESIUM
Expected-S+17 Approximate, Expires-S+365, Routine
GLUCOSE
Expected-S+17 Approximate, Expires-S+365, Routine
BUN
Expected-S+17 Approximate, Expires-S+365, Routine
CREATININE
Expected-S+17 Approximate, Expires-S+365, Routine
URINALYSIS, NO MICROSCOPY
Expected-S+17 Approximate, Expires-S+365, Normal, Routine
Treatment Conditions
Verify Labs
Verify pretreatment labs have been obtained and resulted: CBC, ANC, Urine Heme.
Monitoring Parameters (1)
Hold and notify authorizing prescriber for ANC less than or equal to 1,500/µL or Platelets less than or equal to 100K/µL or Urine
Hemoglobin greater than Trace or Creatinine greater than upper limits of normal.
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
6/6/2017 5:07:26 PM Page 27 of 40
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 06/2017CCKM@uwhealth.org

Nursing Procedure, Assessment and Monitoring
Flush Venous Access Device per Guidelines
Order details
sodium chloride flush 0.9% 10 mL injection
Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin lock flush 10 UNIT/ML injection 1-150 units
1-150 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin 100 UNIT/ML lock flush injection 500 units
500 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Implanted port use ONLY to be used when de-accessing port. Flush per VAD guidelines.
Hydration
sodium chloride 0.9 % infusion
at 250-500 mL/hr, Intravenous, ONCE, 1 dose Starting when released
Infuse 1000 mL throughout treatment.
Pre-Medications
ondansetron (ZOFRAN) tab 16 mg
16 mg, Oral, ONCE, 1 dose Starting when released
dexamethasone (DECADRON) tab 10 mg
10 mg, Oral, ONCE, 1 dose Starting when released
Treatment Medications
mesna (MESNEX) 1,000 mg in sodium chloride 0.9 % 50 mL bag
1,000 mg (500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
ifosfamide (IFEX) 3,000 mg in sodium chloride 0.9 % 250 mL bag
3,000 mg (1,500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
If prior radiotherapy or chemotherapy give ifosfamide 1200mg/m2 IV once daily for 5 days.
Take Home Medications
mesna (MESNEX) 400 MG tab
Take 2.5 tabs by mouth 2 times daily. Take 4 & 8 hours after start of ifosfamide Day 1 thru 5., 1,000 mg (500 mg/m2 × 2 m2
Treatment plan BSA from recorded weight), R-0, 2 X DAILY starting S
Follow-Up
DAY 2 FOLLOW-UP
LABS: Urinalysis without Microscopy; CHEMOTHERAPY ROOM APPOINTMENT: ifosfamide and mesna for 200 minutes.
DAY 3 FOLLOW-UP
LABS: Urinalysis without Microscopy; CHEMOTHERAPY ROOM APPOINTMENT: ifosfamide and mesna for 200 minutes.
DAY 4 FOLLOW-UP
LABS: Urinalysis without Microscopy; CHEMOTHERAPY ROOM APPOINTMENT: ifosfamide and mesna for 200 minutes.
DAY 5 FOLLOW-UP
LABS: Urinalysis without Microscopy; CHEMOTHERAPY ROOM APPOINTMENT: ifosfamide and mesna for 200 minutes.
DAY 10 FOLLOW-UP
LABS: CBC, ANC (DIFF if to be done locally)
DAY 22 FOLLOW-UP
(Day 1 of next cycle) RETURN TO CLINIC for appointment with provider; LABS: CBC, ANC (DIFF if to be done locally), Electrolytes,
Magnesium, Glucose, BUN, Creatinine, Urinalysis without Microscopy; CHEMOTHERAPY ROOM APPOINTMENT: ifosfamide and
mesna for 200 minutes.
Day 2, Cycle 5 – Planned for 8/30/2017
Treatment Plan Information
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
6/6/2017 5:07:26 PM Page 28 of 40
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 06/2017CCKM@uwhealth.org

Treatment Plan Summary
DISEASE: Cervical Cancer (Advanced) Vulvar/Vaginal (Advanced) and Uterine Sarcoma (Adjuvant/Advanced); THERAPY: mesna
500 mg/m2 IV prior ifosfamide on Day 1 through 5; ifosfamide 1500 mg/m2 IV on Day 1 through 5; mesna 500 mg/m2 by mouth 4
hours and 8 hours after the start of ifosfamide; CYCLE LENGTH: 21 days; COURSE: 6 cycles.
Note: If prior radiotherapy or chemotherapy give ifosfamide 1200 mg/m2 IV on Day 1 through 5.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
URINALYSIS, NO MICROSCOPY
Expected-S+1 Approximate, Expires-S+365, Normal, Routine
Treatment Conditions
Verify Labs
Verify pretreatment labs have been obtained and resulted: Urine Heme.
Treatment Parameters
Hold and notify authorizing prescriber for Urine Hemoglobin greater than Trace.
Nursing Procedure, Assessment and Monitoring
Flush Venous Access Device per Guidelines
Order details
sodium chloride flush 0.9% 10 mL injection
Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin lock flush 10 UNIT/ML injection 1-150 units
1-150 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin 100 UNIT/ML lock flush injection 500 units
500 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Implanted port use ONLY to be used when de-accessing port. Flush per VAD guidelines.
Hydration
sodium chloride 0.9 % infusion
at 250-500 mL/hr, Intravenous, ONCE, 1 dose Starting when released
Infuse 1000 mL throughout treatment.
Pre-Medications
ondansetron (ZOFRAN) tab 16 mg
16 mg, Oral, ONCE, 1 dose Starting when released
dexamethasone (DECADRON) tab 10 mg
10 mg, Oral, ONCE, 1 dose Starting when released
Treatment Medications
mesna (MESNEX) 1,000 mg in sodium chloride 0.9 % 50 mL bag
1,000 mg (500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
ifosfamide (IFEX) 3,000 mg in sodium chloride 0.9 % 250 mL bag
3,000 mg (1,500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
If prior radiotherapy or chemotherapy give ifosfamide 1200mg/m2 IV once daily for 5 days.
Follow-Up
VERIFY APPOINTMENTS
Verify next day appointment(s) have been scheduled. See follow-up section on Day 1.
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
6/6/2017 5:07:26 PM Page 29 of 40
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 06/2017CCKM@uwhealth.org

Day 3, Cycle 5 – Planned for 8/31/2017
Treatment Plan Information
Treatment Plan Summary
DISEASE: Cervical Cancer (Advanced) Vulvar/Vaginal (Advanced) and Uterine Sarcoma (Adjuvant/Advanced); THERAPY: mesna
500 mg/m2 IV prior ifosfamide on Day 1 through 5; ifosfamide 1500 mg/m2 IV on Day 1 through 5; mesna 500 mg/m2 by mouth 4
hours and 8 hours after the start of ifosfamide; CYCLE LENGTH: 21 days; COURSE: 6 cycles.
Note: If prior radiotherapy or chemotherapy give ifosfamide 1200 mg/m2 IV on Day 1 through 5.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
URINALYSIS, NO MICROSCOPY
Expected-S+1 Approximate, Expires-S+365, Normal, Routine
Treatment Conditions
Verify Labs
Verify pretreatment labs have been obtained and resulted: Urine Heme.
Treatment Parameters
Hold and notify authorizing prescriber for Urine Hemoglobin greater than Trace.
Nursing Procedure, Assessment and Monitoring
Flush Venous Access Device per Guidelines
Order details
sodium chloride flush 0.9% 10 mL injection
Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin lock flush 10 UNIT/ML injection 1-150 units
1-150 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin 100 UNIT/ML lock flush injection 500 units
500 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Implanted port use ONLY to be used when de-accessing port. Flush per VAD guidelines.
Hydration
sodium chloride 0.9 % infusion
at 250-500 mL/hr, Intravenous, ONCE, 1 dose Starting when released
Infuse 1000 mL throughout treatment.
Pre-Medications
ondansetron (ZOFRAN) tab 16 mg
16 mg, Oral, ONCE, 1 dose Starting when released
dexamethasone (DECADRON) tab 10 mg
10 mg, Oral, ONCE, 1 dose Starting when released
Treatment Medications
mesna (MESNEX) 1,000 mg in sodium chloride 0.9 % 50 mL bag
1,000 mg (500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
ifosfamide (IFEX) 3,000 mg in sodium chloride 0.9 % 250 mL bag
3,000 mg (1,500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
If prior radiotherapy or chemotherapy give ifosfamide 1200mg/m2 IV once daily for 5 days.
Follow-Up
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
6/6/2017 5:07:26 PM Page 30 of 40
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 06/2017CCKM@uwhealth.org

VERIFY APPOINTMENTS
Verify next day appointment(s) have been scheduled. See follow-up section on Day 1.
Day 4, Cycle 5 – Planned for 9/1/2017
Treatment Plan Information
Treatment Plan Summary
DISEASE: Cervical Cancer (Advanced) Vulvar/Vaginal (Advanced) and Uterine Sarcoma (Adjuvant/Advanced); THERAPY: mesna
500 mg/m2 IV prior ifosfamide on Day 1 through 5; ifosfamide 1500 mg/m2 IV on Day 1 through 5; mesna 500 mg/m2 by mouth 4
hours and 8 hours after the start of ifosfamide; CYCLE LENGTH: 21 days; COURSE: 6 cycles.
Note: If prior radiotherapy or chemotherapy give ifosfamide 1200 mg/m2 IV on Day 1 through 5.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
URINALYSIS, NO MICROSCOPY
Expected-S+1 Approximate, Expires-S+365, Normal, Routine
Treatment Conditions
Verify Labs
Verify pretreatment labs have been obtained and resulted: Urine Heme.
Treatment Parameters
Hold and notify authorizing prescriber for Urine Hemoglobin greater than Trace.
Nursing Procedure, Assessment and Monitoring
Flush Venous Access Device per Guidelines
Order details
sodium chloride flush 0.9% 10 mL injection
Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin lock flush 10 UNIT/ML injection 1-150 units
1-150 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin 100 UNIT/ML lock flush injection 500 units
500 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Implanted port use ONLY to be used when de-accessing port. Flush per VAD guidelines.
Hydration
sodium chloride 0.9 % infusion
at 250-500 mL/hr, Intravenous, ONCE, 1 dose Starting when released
Infuse 1000 mL throughout treatment.
Pre-Medications
ondansetron (ZOFRAN) tab 16 mg
16 mg, Oral, ONCE, 1 dose Starting when released
dexamethasone (DECADRON) tab 10 mg
10 mg, Oral, ONCE, 1 dose Starting when released
Treatment Medications
mesna (MESNEX) 1,000 mg in sodium chloride 0.9 % 50 mL bag
1,000 mg (500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
ifosfamide (IFEX) 3,000 mg in sodium chloride 0.9 % 250 mL bag
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
6/6/2017 5:07:26 PM Page 31 of 40
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 06/2017CCKM@uwhealth.org

3,000 mg (1,500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
If prior radiotherapy or chemotherapy give ifosfamide 1200mg/m2 IV once daily for 5 days.
Follow-Up
VERIFY APPOINTMENTS
Verify next day appointment(s) have been scheduled. See follow-up section on Day 1.
Day 5, Cycle 5 – Planned for 9/2/2017
Treatment Plan Information
Treatment Plan Summary
DISEASE: Cervical Cancer (Advanced) Vulvar/Vaginal (Advanced) and Uterine Sarcoma (Adjuvant/Advanced); THERAPY: mesna
500 mg/m2 IV prior ifosfamide on Day 1 through 5; ifosfamide 1500 mg/m2 IV on Day 1 through 5; mesna 500 mg/m2 by mouth 4
hours and 8 hours after the start of ifosfamide; CYCLE LENGTH: 21 days; COURSE: 6 cycles.
Note: If prior radiotherapy or chemotherapy give ifosfamide 1200 mg/m2 IV on Day 1 through 5.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
URINALYSIS, NO MICROSCOPY
Expected-S+1 Approximate, Expires-S+365, Normal, Routine
Treatment Conditions
Verify Labs
Verify pretreatment labs have been obtained and resulted: Urine Heme.
Treatment Parameters
Hold and notify authorizing prescriber for Urine Hemoglobin greater than Trace.
Nursing Procedure, Assessment and Monitoring
Flush Venous Access Device per Guidelines
Order details
sodium chloride flush 0.9% 10 mL injection
Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin lock flush 10 UNIT/ML injection 1-150 units
1-150 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin 100 UNIT/ML lock flush injection 500 units
500 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Implanted port use ONLY to be used when de-accessing port. Flush per VAD guidelines.
Hydration
sodium chloride 0.9 % infusion
at 250-500 mL/hr, Intravenous, ONCE, 1 dose Starting when released
Infuse 1000 mL throughout treatment.
Pre-Medications
ondansetron (ZOFRAN) tab 16 mg
16 mg, Oral, ONCE, 1 dose Starting when released
dexamethasone (DECADRON) tab 10 mg
10 mg, Oral, ONCE, 1 dose Starting when released
Treatment Medications
mesna (MESNEX) 1,000 mg in sodium chloride 0.9 % 50 mL bag
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
6/6/2017 5:07:26 PM Page 32 of 40
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 06/2017CCKM@uwhealth.org

1,000 mg (500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
ifosfamide (IFEX) 3,000 mg in sodium chloride 0.9 % 250 mL bag
3,000 mg (1,500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
If prior radiotherapy or chemotherapy give ifosfamide 1200mg/m2 IV once daily for 5 days.
Follow-Up
VERIFY APPOINTMENTS
Verify next day appointment(s) have been scheduled. See follow-up section on Day 1.
Day 10 - Lab Only, Cycle 5 – Planned for 9/7/2017
Treatment Plan Information
Treatment Plan Summary
DISEASE: Cervical Cancer (Advanced) Vulvar/Vaginal (Advanced) and Uterine Sarcoma (Adjuvant/Advanced); THERAPY: mesna
500 mg/m2 IV prior ifosfamide on Day 1 through 5; ifosfamide 1500 mg/m2 IV on Day 1 through 5; mesna 500 mg/m2 by mouth 4
hours and 8 hours after the start of ifosfamide; CYCLE LENGTH: 21 days; COURSE: 6 cycles.
Note: If prior radiotherapy or chemotherapy give ifosfamide 1200 mg/m2 IV on Day 1 through 5.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
CBC WITHOUT DIFFERENTIAL
Expected-S+5 Approximate, Expires-S+365, Routine
ABSOLUTE NEUTROPHIL COUNT
Expected-S+5 Approximate, Expires-S+365, Routine
Follow-Up
VERIFY APPOINTMENTS
Verify next day appointment(s) have been scheduled. See follow-up section on Day 1.
Cycle 6 – 9/19/2017 through 10/9/2017 (21 days), Planned
Day 1, Cycle 6 – Planned for 9/19/2017
Treatment Plan Information
Treatment Plan Summary
DISEASE: Cervical Cancer (Advanced) Vulvar/Vaginal (Advanced) and Uterine Sarcoma (Adjuvant/Advanced); THERAPY: mesna
500 mg/m2 IV prior ifosfamide on Day 1 through 5; ifosfamide 1500 mg/m2 IV on Day 1 through 5; mesna 500 mg/m2 by mouth 4
hours and 8 hours after the start of ifosfamide; CYCLE LENGTH: 21 days; COURSE: 6 cycles.
Note: If prior radiotherapy or chemotherapy give ifosfamide 1200 mg/m2 IV on Day 1 through 5.
Consent
Verify Consent
Verify informed consent has been obtained.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
CBC WITHOUT DIFFERENTIAL
Expected-S+17 Approximate, Expires-S+365, Routine
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
6/6/2017 5:07:26 PM Page 33 of 40
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 06/2017CCKM@uwhealth.org

ABSOLUTE NEUTROPHIL COUNT
Expected-S+17 Approximate, Expires-S+365, Routine
ELECTROLYTES
Expected-S+17 Approximate, Expires-S+365, Routine
MAGNESIUM
Expected-S+17 Approximate, Expires-S+365, Routine
GLUCOSE
Expected-S+17 Approximate, Expires-S+365, Routine
BUN
Expected-S+17 Approximate, Expires-S+365, Routine
CREATININE
Expected-S+17 Approximate, Expires-S+365, Routine
URINALYSIS, NO MICROSCOPY
Expected-S+17 Approximate, Expires-S+365, Normal, Routine
Treatment Conditions
Verify Labs
Verify pretreatment labs have been obtained and resulted: CBC, ANC, Urine Heme.
Monitoring Parameters (1)
Hold and notify authorizing prescriber for ANC less than or equal to 1,500/µL or Platelets less than or equal to 100K/µL or Urine
Hemoglobin greater than Trace or Creatinine greater than upper limits of normal.
Nursing Procedure, Assessment and Monitoring
Flush Venous Access Device per Guidelines
Order details
sodium chloride flush 0.9% 10 mL injection
Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin lock flush 10 UNIT/ML injection 1-150 units
1-150 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin 100 UNIT/ML lock flush injection 500 units
500 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Implanted port use ONLY to be used when de-accessing port. Flush per VAD guidelines.
Hydration
sodium chloride 0.9 % infusion
at 250-500 mL/hr, Intravenous, ONCE, 1 dose Starting when released
Infuse 1000 mL throughout treatment.
Pre-Medications
ondansetron (ZOFRAN) tab 16 mg
16 mg, Oral, ONCE, 1 dose Starting when released
dexamethasone (DECADRON) tab 10 mg
10 mg, Oral, ONCE, 1 dose Starting when released
Treatment Medications
mesna (MESNEX) 1,000 mg in sodium chloride 0.9 % 50 mL bag
1,000 mg (500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
ifosfamide (IFEX) 3,000 mg in sodium chloride 0.9 % 250 mL bag
3,000 mg (1,500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
If prior radiotherapy or chemotherapy give ifosfamide 1200mg/m2 IV once daily for 5 days.
Take Home Medications
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
6/6/2017 5:07:26 PM Page 34 of 40
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 06/2017CCKM@uwhealth.org

mesna (MESNEX) 400 MG tab
Take 2.5 tabs by mouth 2 times daily. Take 4 & 8 hours after start of ifosfamide Day 1 thru 5., 1,000 mg (500
mg/m2 × 2 m2 Treatment plan BSA from recorded weight), R-0, 2 X DAILY starting S
Follow-Up
DAY 2 FOLLOW-UP
LABS: Urinalysis without Microscopy; CHEMOTHERAPY ROOM APPOINTMENT: ifosfamide and mesna for 200 minutes.
DAY 3 FOLLOW-UP
LABS: Urinalysis without Microscopy; CHEMOTHERAPY ROOM APPOINTMENT: ifosfamide and mesna for 200 minutes.
DAY 4 FOLLOW-UP
LABS: Urinalysis without Microscopy; CHEMOTHERAPY ROOM APPOINTMENT: ifosfamide and mesna for 200 minutes.
DAY 5 FOLLOW-UP
LABS: Urinalysis without Microscopy; CHEMOTHERAPY ROOM APPOINTMENT: ifosfamide and mesna for 200 minutes.
DAY 10 FOLLOW-UP
LABS: CBC, ANC (DIFF if to be done locally)
DAY 22 FOLLOW-UP
(Day 1 of next cycle) RETURN TO CLINIC for appointment with provider; LABS: CBC, ANC (DIFF if to be done locally), Electrolytes,
Magnesium, Glucose, BUN, Creatinine, Urinalysis without Microscopy; CHEMOTHERAPY ROOM APPOINTMENT: ifosfamide and
mesna for 200 minutes.
Day 2, Cycle 6 – Planned for 9/20/2017
Treatment Plan Information
Treatment Plan Summary
DISEASE: Cervical Cancer (Advanced) Vulvar/Vaginal (Advanced) and Uterine Sarcoma (Adjuvant/Advanced); THERAPY: mesna
500 mg/m2 IV prior ifosfamide on Day 1 through 5; ifosfamide 1500 mg/m2 IV on Day 1 through 5; mesna 500 mg/m2 by mouth 4
hours and 8 hours after the start of ifosfamide; CYCLE LENGTH: 21 days; COURSE: 6 cycles.
Note: If prior radiotherapy or chemotherapy give ifosfamide 1200 mg/m2 IV on Day 1 through 5.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
URINALYSIS, NO MICROSCOPY
Expected-S+1 Approximate, Expires-S+365, Normal, Routine
Treatment Conditions
Verify Labs
Verify pretreatment labs have been obtained and resulted: Urine Heme.
Treatment Parameters
Hold and notify authorizing prescriber for Urine Hemoglobin greater than Trace.
Nursing Procedure, Assessment and Monitoring
Flush Venous Access Device per Guidelines
Order details
sodium chloride flush 0.9% 10 mL injection
Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin lock flush 10 UNIT/ML injection 1-150 units
1-150 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin 100 UNIT/ML lock flush injection 500 units
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
6/6/2017 5:07:26 PM Page 35 of 40
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 06/2017CCKM@uwhealth.org

500 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Implanted port use ONLY to be used when de-accessing port. Flush per VAD guidelines.
Hydration
sodium chloride 0.9 % infusion
at 250-500 mL/hr, Intravenous, ONCE, 1 dose Starting when released
Infuse 1000 mL throughout treatment.
Pre-Medications
ondansetron (ZOFRAN) tab 16 mg
16 mg, Oral, ONCE, 1 dose Starting when released
dexamethasone (DECADRON) tab 10 mg
10 mg, Oral, ONCE, 1 dose Starting when released
Treatment Medications
mesna (MESNEX) 1,000 mg in sodium chloride 0.9 % 50 mL bag
1,000 mg (500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
ifosfamide (IFEX) 3,000 mg in sodium chloride 0.9 % 250 mL bag
3,000 mg (1,500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
If prior radiotherapy or chemotherapy give ifosfamide 1200mg/m2 IV once daily for 5 days.
Follow-Up
VERIFY APPOINTMENTS
Verify next day appointment(s) have been scheduled. See follow-up section on Day 1.
Day 3, Cycle 6 – Planned for 9/21/2017
Treatment Plan Information
Treatment Plan Summary
DISEASE: Cervical Cancer (Advanced) Vulvar/Vaginal (Advanced) and Uterine Sarcoma (Adjuvant/Advanced); THERAPY: mesna
500 mg/m2 IV prior ifosfamide on Day 1 through 5; ifosfamide 1500 mg/m2 IV on Day 1 through 5; mesna 500 mg/m2 by mouth 4
hours and 8 hours after the start of ifosfamide; CYCLE LENGTH: 21 days; COURSE: 6 cycles.
Note: If prior radiotherapy or chemotherapy give ifosfamide 1200 mg/m2 IV on Day 1 through 5.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
URINALYSIS, NO MICROSCOPY
Expected-S+1 Approximate, Expires-S+365, Normal, Routine
Treatment Conditions
Verify Labs
Verify pretreatment labs have been obtained and resulted: Urine Heme.
Treatment Parameters
Hold and notify authorizing prescriber for Urine Hemoglobin greater than Trace.
Nursing Procedure, Assessment and Monitoring
Flush Venous Access Device per Guidelines
Order details
sodium chloride flush 0.9% 10 mL injection
Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin lock flush 10 UNIT/ML injection 1-150 units
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
6/6/2017 5:07:26 PM Page 36 of 40
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 06/2017CCKM@uwhealth.org

1-150 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin 100 UNIT/ML lock flush injection 500 units
500 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Implanted port use ONLY to be used when de-accessing port. Flush per VAD guidelines.
Hydration
sodium chloride 0.9 % infusion
at 250-500 mL/hr, Intravenous, ONCE, 1 dose Starting when released
Infuse 1000 mL throughout treatment.
Pre-Medications
ondansetron (ZOFRAN) tab 16 mg
16 mg, Oral, ONCE, 1 dose Starting when released
dexamethasone (DECADRON) tab 10 mg
10 mg, Oral, ONCE, 1 dose Starting when released
Treatment Medications
mesna (MESNEX) 1,000 mg in sodium chloride 0.9 % 50 mL bag
1,000 mg (500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
ifosfamide (IFEX) 3,000 mg in sodium chloride 0.9 % 250 mL bag
3,000 mg (1,500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
If prior radiotherapy or chemotherapy give ifosfamide 1200mg/m2 IV once daily for 5 days.
Follow-Up
VERIFY APPOINTMENTS
Verify next day appointment(s) have been scheduled. See follow-up section on Day 1.
Day 4, Cycle 6 – Planned for 9/22/2017
Treatment Plan Information
Treatment Plan Summary
DISEASE: Cervical Cancer (Advanced) Vulvar/Vaginal (Advanced) and Uterine Sarcoma (Adjuvant/Advanced); THERAPY: mesna
500 mg/m2 IV prior ifosfamide on Day 1 through 5; ifosfamide 1500 mg/m2 IV on Day 1 through 5; mesna 500 mg/m2 by mouth 4
hours and 8 hours after the start of ifosfamide; CYCLE LENGTH: 21 days; COURSE: 6 cycles.
Note: If prior radiotherapy or chemotherapy give ifosfamide 1200 mg/m2 IV on Day 1 through 5.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
URINALYSIS, NO MICROSCOPY
Expected-S+1 Approximate, Expires-S+365, Normal, Routine
Treatment Conditions
Verify Labs
Verify pretreatment labs have been obtained and resulted: Urine Heme.
Treatment Parameters
Hold and notify authorizing prescriber for Urine Hemoglobin greater than Trace.
Nursing Procedure, Assessment and Monitoring
Flush Venous Access Device per Guidelines
Order details
sodium chloride flush 0.9% 10 mL injection
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
6/6/2017 5:07:26 PM Page 37 of 40
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 06/2017CCKM@uwhealth.org

Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin lock flush 10 UNIT/ML injection 1-150 units
1-150 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin 100 UNIT/ML lock flush injection 500 units
500 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Implanted port use ONLY to be used when de-accessing port. Flush per VAD guidelines.
Hydration
sodium chloride 0.9 % infusion
at 250-500 mL/hr, Intravenous, ONCE, 1 dose Starting when released
Infuse 1000 mL throughout treatment.
Pre-Medications
ondansetron (ZOFRAN) tab 16 mg
16 mg, Oral, ONCE, 1 dose Starting when released
dexamethasone (DECADRON) tab 10 mg
10 mg, Oral, ONCE, 1 dose Starting when released
Treatment Medications
mesna (MESNEX) 1,000 mg in sodium chloride 0.9 % 50 mL bag
1,000 mg (500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
ifosfamide (IFEX) 3,000 mg in sodium chloride 0.9 % 250 mL bag
3,000 mg (1,500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
If prior radiotherapy or chemotherapy give ifosfamide 1200mg/m2 IV once daily for 5 days.
Follow-Up
VERIFY APPOINTMENTS
Verify next day appointment(s) have been scheduled. See follow-up section on Day 1.
Day 5, Cycle 6 – Planned for 9/23/2017
Treatment Plan Information
Treatment Plan Summary
DISEASE: Cervical Cancer (Advanced) Vulvar/Vaginal (Advanced) and Uterine Sarcoma (Adjuvant/Advanced); THERAPY: mesna
500 mg/m2 IV prior ifosfamide on Day 1 through 5; ifosfamide 1500 mg/m2 IV on Day 1 through 5; mesna 500 mg/m2 by mouth 4
hours and 8 hours after the start of ifosfamide; CYCLE LENGTH: 21 days; COURSE: 6 cycles.
Note: If prior radiotherapy or chemotherapy give ifosfamide 1200 mg/m2 IV on Day 1 through 5.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
URINALYSIS, NO MICROSCOPY
Expected-S+1 Approximate, Expires-S+365, Normal, Routine
Treatment Conditions
Verify Labs
Verify pretreatment labs have been obtained and resulted: Urine Heme.
Treatment Parameters
Hold and notify authorizing prescriber for Urine Hemoglobin greater than Trace.
Nursing Procedure, Assessment and Monitoring
Flush Venous Access Device per Guidelines
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
6/6/2017 5:07:26 PM Page 38 of 40
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 06/2017CCKM@uwhealth.org

Order details
sodium chloride flush 0.9% 10 mL injection
Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin lock flush 10 UNIT/ML injection 1-150 units
1-150 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin 100 UNIT/ML lock flush injection 500 units
500 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Implanted port use ONLY to be used when de-accessing port. Flush per VAD guidelines.
Hydration
sodium chloride 0.9 % infusion
at 250-500 mL/hr, Intravenous, ONCE, 1 dose Starting when released
Infuse 1000 mL throughout treatment.
Pre-Medications
ondansetron (ZOFRAN) tab 16 mg
16 mg, Oral, ONCE, 1 dose Starting when released
dexamethasone (DECADRON) tab 10 mg
10 mg, Oral, ONCE, 1 dose Starting when released
Treatment Medications
mesna (MESNEX) 1,000 mg in sodium chloride 0.9 % 50 mL bag
1,000 mg (500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
ifosfamide (IFEX) 3,000 mg in sodium chloride 0.9 % 250 mL bag
3,000 mg (1,500 mg/m2 × 2 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released
If prior radiotherapy or chemotherapy give ifosfamide 1200mg/m2 IV once daily for 5 days.
Follow-Up
VERIFY APPOINTMENTS
Verify next day appointment(s) have been scheduled. See follow-up section on Day 1.
Day 10 - Lab Only, Cycle 6 – Planned for 9/28/2017
Treatment Plan Information
Treatment Plan Summary
DISEASE: Cervical Cancer (Advanced) Vulvar/Vaginal (Advanced) and Uterine Sarcoma (Adjuvant/Advanced); THERAPY: mesna
500 mg/m2 IV prior ifosfamide on Day 1 through 5; ifosfamide 1500 mg/m2 IV on Day 1 through 5; mesna 500 mg/m2 by mouth 4
hours and 8 hours after the start of ifosfamide; CYCLE LENGTH: 21 days; COURSE: 6 cycles.
Note: If prior radiotherapy or chemotherapy give ifosfamide 1200 mg/m2 IV on Day 1 through 5.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
CBC WITHOUT DIFFERENTIAL
Expected-S+5 Approximate, Expires-S+365, Routine
ABSOLUTE NEUTROPHIL COUNT
Expected-S+5 Approximate, Expires-S+365, Routine
Follow-Up
VERIFY APPOINTMENTS
Verify next day appointment(s) have been scheduled. See follow-up section on Day 1.
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Edward E [2435061]
6/6/2017 5:07:26 PM Page 39 of 40
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 06/2017CCKM@uwhealth.org

Zztestonc,Edward E [2435061]
6/6/2017 5:07:26 PM Page 40 of 40
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 06/2017CCKM@uwhealth.org